ANMAT Provision 7939/2025 represents one of the most substantial regulatory updates for Argentina’s cosmetics, personal care, and household hygiene sectors. The new framework modernizes the process for authorizing establishments engaged in manufacturing, packaging, fractioning, conditioning, and importing…
On September 5, 2025, the National Administration of Medicines, Food, and Medical Technology (ANMAT) issued Provision No. 6559/2025, expanding the requirement of bioequivalence and/or bioavailability studies to oral pharmaceutical forms of hypoglycemic drugs.
This measure applies to medicinal products whose…
By Adrian Gonzalez.
Can Latin America be a leader in cutting-edge technologies? The answer is clear: hardly. In fact, the region accounts for less than 2% of the world’s patent applications; of these, less than a fifth are filed…
By Moeller IP Advisors
Research and production costs for developing pharmaceuticals are extremely high, especially for biological drugs. Biopharmaceutical companies can expect to spend up to US$ 1.3 billion for developing and testing a single drug, and the costs are…
